IL316091A - Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist - Google Patents

Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist

Info

Publication number
IL316091A
IL316091A IL316091A IL31609124A IL316091A IL 316091 A IL316091 A IL 316091A IL 316091 A IL316091 A IL 316091A IL 31609124 A IL31609124 A IL 31609124A IL 316091 A IL316091 A IL 316091A
Authority
IL
Israel
Prior art keywords
antagonist
administering
compositions
methods
polymyalgia rheumatica
Prior art date
Application number
IL316091A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of IL316091A publication Critical patent/IL316091A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL316091A 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist IL316091A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263327850P 2022-04-06 2022-04-06
US202263350761P 2022-06-09 2022-06-09
US202263389317P 2022-07-14 2022-07-14
US202263424035P 2022-11-09 2022-11-09
US202263424627P 2022-11-11 2022-11-11
US202363445329P 2023-02-14 2023-02-14
US202363445331P 2023-02-14 2023-02-14
US202363447796P 2023-02-23 2023-02-23
PCT/US2023/065361 WO2023196838A1 (en) 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist

Publications (1)

Publication Number Publication Date
IL316091A true IL316091A (en) 2024-12-01

Family

ID=86424726

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316091A IL316091A (en) 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist

Country Status (11)

Country Link
US (1) US20230399410A1 (https=)
EP (1) EP4504788A1 (https=)
JP (2) JP7630012B2 (https=)
KR (1) KR20240164816A (https=)
CN (1) CN120569404A (https=)
AU (1) AU2023250653A1 (https=)
CA (1) CA3247400A1 (https=)
IL (1) IL316091A (https=)
MX (1) MX2024012345A (https=)
TW (1) TW202405014A (https=)
WO (1) WO2023196838A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149845A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025149846A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2017106312A1 (en) * 2015-12-18 2017-06-22 Drexel University Methods of modulating levels of il-6 and pd-l1
EP3980459A1 (en) * 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Also Published As

Publication number Publication date
MX2024012345A (es) 2024-11-08
JP2025072440A (ja) 2025-05-09
TW202405014A (zh) 2024-02-01
US20230399410A1 (en) 2023-12-14
WO2023196838A1 (en) 2023-10-12
AU2023250653A1 (en) 2024-11-21
KR20240164816A (ko) 2024-11-20
EP4504788A1 (en) 2025-02-12
JP2024526414A (ja) 2024-07-18
CA3247400A1 (en) 2023-10-12
JP7630012B2 (ja) 2025-02-14
CN120569404A (zh) 2025-08-29

Similar Documents

Publication Publication Date Title
IL316091A (en) Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist
EP3917620A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS
EP4292588A3 (en) Administration of deuterated cftr potentiators
MX2021010870A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2022005335A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
IL309296A (en) Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
IL294066A (en) Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
IL316907A (en) METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS
IL320362A (en) Methods for treating hand and foot skin infections by administering an IL-4R antagonist
HK40124116A (en) Compositions and methods for treating polymyalgia rheumatica by administering an il-6r antagonist
IL312187A (en) Methods for treating prurigo nodularis by administering an IL-4R antagonist
IL318016A (en) Methods for treating eosinophilic esophagitis in children by administering an IL-4R antagonist
IL316843A (en) Compounds and methods for inhibiting SNCA deactivation
CA3266767A1 (en) ADVANCED COMPOSITIONS AND TREATMENT METHODS FOR SOLID TUMORS
HK40110609A (en) Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
HK40114753A (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
CA3285901A1 (en) Microbiota compositions and methods for treating disorders
HK40111177A (en) Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
HK40084664A (en) Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
AU2023900704A0 (en) Microbiota Compositions and Methods for Treating Disorders
IL326321A (en) Methods and compositions for treating CTNNB1-related disorders
CA3297601A1 (en) Methods and compositions for treating ctnnb1-associated disorders
IL321862A (en) Methods and compounds for treating disorders caused by HSD-1
HK40120097A (en) Methods for treating pediatric eosinophilic esophagitis by administering an il-4r antagonist